A clinical exploratory study on the use of Limertinib sequential combination chemotherapy for advanced NSCLC with EGFR mutations

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 139d747064cd57f2415498b8510600b7786b976e
First added on: Oct 10, 2026